Encouraging Blood Donation in Patients With a Blood Type in Short Supply - Part 2
NCT ID: NCT05825300
Last Updated: 2023-07-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40486 participants
INTERVENTIONAL
2023-04-10
2023-07-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Encouraging Blood Donation in Patients With a Blood Type in Short Supply
NCT05135325
Blood Donor Competence, Autonomy and Relatedness Enhancement
NCT02717338
A Survey of Attitudes of Experienced Blood Donors
NCT03102385
CMSL Ambulatory Sensitive Condition Nudge Study 2
NCT07028398
Message Testing for CKD
NCT05462158
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Because Miller Keystone particularly values reaching new donors, the team ran a preregistered exploratory analysis to test whether the messages were differently effective for new donors compared to those who had previously donated at a Miller Keystone site. There was a significant interaction between previous donor status (previous donor, previous non-donor) and message type, such that previous non-donors were relatively more responsive to the blood-type message, while previous donors were more responsive to the no-blood-type message. However, the groups were uneven with respect to the number of patients that had previously donated. Moreover, when the analysis was limited to patients who opened their messages, this interaction effect disappeared: blood-type messages were still most effective in previous non-donors, and there was no difference in message effectiveness among previous donors. These follow-up analyses, and the unevenness of previous donors across groups, call into question the robustness of the interaction effect.
The present study will again test whether the blood-type message is more effective than the no-blood-type message for patients with needed blood types overall, and separately for previous donors and non-donors. Messages will be sent via email rather than via patient portal in the present study. Randomization will occur at the email-address level to one of the two message types to ensure everyone using the same email address receives the same message (although each patient will be sent an individualized message with their name; there will be no no-contact control condition this time). Email addresses will be excluded if they are shared by patients with different blood types. Randomization will be stratified by whether all patients using the same email address are previous donors or not (email addresses shared by previous donors and non-donors will be excluded).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
No-blood-type message
This group will receive a message that does not mention that the patient's blood type is in short supply.
Email message
Email message encourages patients to donate blood
Blood-type message
This group will receive a message that states their blood type is in short supply.
Email message
Email message encourages patients to donate blood
Social responsibility
Message specifies that there is a shortage of the patient's blood type
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Email message
Email message encourages patients to donate blood
Social responsibility
Message specifies that there is a shortage of the patient's blood type
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18+
* Can be contacted via email
Exclusion Criteria
* Shares an email address with a patient of a different needed blood type
* Email address associated with at least one previous donor and one non-previous donor
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Geisinger Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amir Goren
Program Director, Behavioral Insights Team
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Amir Goren, PhD
Role: PRINCIPAL_INVESTIGATOR
Geisinger Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Geisinger Clinic
Danville, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-0476-2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.